Document:

Exhibit 10.5

Exhibit 10.5

RETENTION AND INCENTIVE AGREEMENT

This Retenion and Incentive Agreement (this “Agreement”) is made as of January 28, 2009 (the
“Effective Date”) by and between Adventrx Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), and Michele L. Yelmene, an individual resident of the State of California (“Employee”).
Certain capitalized terms used in this Agreement are defined in Section 12 below.

1. At-Will Employment. Employee’s employment is and shall continue to be at-will, as
defined under applicable law. If Employee’s employment terminates for any reason, Employee shall
not be entitled to any payments, benefits, damages, awards or compensation other than as provided
by this Agreement or required by applicable law, or as may otherwise be established under the
Company’s then existing employee benefit plans or policies at the time of termination.

2. Severance Benefits. If Employee’s employment with the Company terminates as a
result of an Involuntary Termination at any time, and Employee delivers (and does not revoke) the
Release (as defined in Section 8 below), then Employee shall be entitled to an amount payable by
the Company to Employee equal to the Severance Payment, less applicable withholdings, which amount
shall be payable in a lump-sum on the date determined pursuant to Section 8.

3. Issuance of Restricted Stock Units. The Company shall execute a Notice of Grant of
Restricted Stock Units in substantially the form of Exhibit A attached hereto pursuant to which
Employee shall be granted an award of Restricted Stock Units pursuant to the Company’s 2008 Omnibus
Incentive Plan (the “Award”); provided, however, that the Company has received a written waiver
under that certain Rights Agreement, dated July 25, 2005, as amended (the “Rights Agreement”), that
allows the Company to grant the Award without complying with the participation rights (and any
related rights, including rights to notice) set forth in the Rights Agreement.

4. Other Terminations. If Employee’s employment with the Company is terminated, other
than as a result of an Involuntary Termination, then Employee shall not be entitled to the benefits
of Section 2 of this Agreement.

5. Accrued Wages and Vacation, Expenses. Without regard to the reason for, or the
timing of, Employee’s termination of employment: (i) the Company shall pay Employee any unpaid base
salary due for periods prior to and including the Termination Date; (ii) the Company shall pay
Employee all of Employee’s accrued and unused vacation through the Termination Date; and (iii)
following submission of proper expense reports by Employee, the Company shall reimburse Employee
for all expenses reasonably and necessarily incurred by Employee in connection with the business of
the Company prior to the Termination Date. These payments shall be made promptly upon termination
and within the period of time mandated by law (including but limited to Section 409A of the
Internal Revenue Code of 1986, as amended (the “Code”)).

 

 

 

6. Limitation on Payments. In the event it shall be determined that any compensation
by or benefit from the Company to Employee or for Employee’s benefit, whether pursuant to the terms
of this Agreement or otherwise (collectively, the “Payments”), (i) constitute “parachute payments”
within the meaning of Section 280G of the Code, and (ii) would be subject to the excise tax imposed
by Section 4999 of the Code (the “Excise Tax”), then Employee’s benefits under this Agreement shall
be either:

(a) delivered in full, or

(b) delivered as to such lesser extent which would result in no portion of such benefits being
subject to the Excise Tax,

whichever of the foregoing amounts, taking into account the applicable federal, state and local
income taxes and the Excise Tax, results in the receipt by Employee on an after-tax basis of the
greatest amount of benefits, notwithstanding that all or some portion of such benefits may be
taxable under Section 4999 of the Code.

Unless the Company and Employee otherwise agree in writing, any determination required under
this Section 6 shall be made in writing by the Company’s independent public accountants (the
“Accountants”), whose determination shall be conclusive and binding upon Employee and the Company
for all purposes. For purposes of making the calculations required by this Section 6, the
Accountants may make reasonable assumptions and approximations concerning applicable taxes and may
rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999
of the Code. The Company and Employee shall furnish to the Accountants such information and
documents as the Accountants may reasonably request in order to make a determination under this
Section 6. The Company shall bear all costs the Accountants may reasonably incur in connection
with any calculations contemplated by this Section 6.

In the event that Payments must be reduced, then the Payments will be reduced in accordance
with the following order of priority: (a) first, Full Credit Payments (as defined below) will be
reduced in reverse chronological order such that the payment owed on the latest date following the
occurrence of the event triggering the Excise Tax will be the first Payment to be reduced until
such Payment is reduced to zero, and then the Payment owed on the next latest date following
occurrence of the event triggering the Excise Tax will be the second Payment to be reduced until
such payment is equal to zero, and so forth, until all such Full Credit Payments have been reduced
to zero, and (b) second, Partial Credit Payments (as defined below) will be reduced in a manner
such as to obtain the best economic benefit for the employee so that after giving effect to such
reduction, the employee retains the greatest economic value of such Partial Credit Payments. “Full
Credit Payment” means a payment, distribution or benefit, whether paid or payable or distributed or
distributable pursuant to the terms of this Agreement or otherwise, that if reduced in value by one
dollar reduces the amount of the parachute payment by one dollar. “Partial Credit Payment” means a
payment, distribution or benefit, whether paid or payable or distributed or distributable pursuant
to the terms of this letter or otherwise, that if reduced in value by one dollar reduces the amount
of the parachute payment by an amount that is less than one dollar. For clarification purposes
only, a “Partial Credit Payment” would include a stock
option as to which vesting is accelerated upon an event that triggers the Excise Tax, where
the in the money value of the option exceeds the value of the option acceleration that is added to
the parachute payment.

 

 

 

7. Company’s Successors. Any successor to the Company (whether direct or indirect and
whether by purchase, license, lease, merger, consolidation, liquidation or otherwise) to all or
substantially all of the Company’s business and/or assets shall not later than the closing or
consummation of such succession assume the Company’s obligations under this Agreement and agree
expressly to perform the Company’s obligations under this Agreement in the same manner and to the
same extent as the Company would be required to perform such obligations in the absence of a
succession. For all purposes under this Agreement, the term “Company” shall include any successor
to the Company’s business and/or assets which executes and delivers the assumption agreement
described in this section or which becomes bound by the terms of this Agreement by operation of
law.

8. Execution of Release Agreement upon Termination. As a condition of receiving the
benefits under Section 2 of this Agreement, Employee shall execute and not revoke a general release
of claims, which will also confirm any post-termination obligations and/or restrictions applicable
to Employee (the “Release”), such that the Release becomes effective no later than 60 days
following the Termination Date (the “Release Deadline”). The benefits under Section 2 shall be
paid on the date the Release is effective; provided, however, that, in the event Employee’s
separation occurs at a time during the calendar year where it would be possible for the Release to
become effective in the calendar year following the calendar year in which Employee’s separation
occurs, any severance that would be considered deferred compensation (as defined in Section 409A of
the Code) will be paid on the first payroll date to occur immediately following the Release
Deadline.

9. Notices.

(a) General. Notices and all other communications contemplated by this Agreement
shall be in writing and shall be deemed to have been duly given when personally delivered or when
mailed by U.S. registered or certified mail, return receipt requested and postage prepaid. In the
case of Employee, mailed notices shall be addressed to him or her at the home address that he or
she most recently communicated to the Company in writing. In the case of the Company, mailed
notices shall be addressed to its corporate headquarters, and all notices shall be directed to the
attention of its Secretary.

(b) Notice of Termination. Any termination by the Company with or without Cause or by
Employee as a result of an Involuntary Termination other than an Involuntary Termination pursuant
to Section 12(b)(vi) shall be communicated by a notice of termination to the other party hereto
given in accordance with this Section 9. Any such notice provided by the Company under
circumstances constituting a for-Cause termination, or by Employee under circumstances constituting
such an Involuntary Termination, shall indicate the specific termination provision in this
Agreement relied upon, shall set forth in reasonable detail the facts and circumstances claimed to
provide a basis for termination under the provision so indicated, and shall specify the Termination
Date (which shall be not more than 30 days after the giving of such
notice). The failure by either party to include in the notice any fact or circumstance which
contributes to a showing of a for-Cause termination or an Involuntary Termination shall not waive
any right of such party hereunder or preclude such party from asserting such fact or circumstance
in enforcing such party’s rights hereunder.

 

 

 

10. Arbitration.

(a) Any dispute or controversy arising out of, relating to, or in connection with this
Agreement, or the interpretation, validity, construction, performance, breach, or termination
thereof, shall be settled by binding arbitration to be held in the County of San Diego, State of
California in accordance with the National Rules for the Resolution of Employment Disputes then in
effect of the American Arbitration Association (the “Rules”). The arbitrator may grant injunctions
or other relief in such dispute or controversy. The decision of the arbitrator shall be final,
conclusive and binding on the parties to the arbitration. Judgment may be entered on the
arbitrator’s decision in any court having jurisdiction.

(b) The arbitrator(s) shall apply California law to the merits of any dispute or claim,
without reference to conflicts of law rules. The arbitration proceedings shall be governed by
federal arbitration law and by the Rules, without reference to state arbitration law. Employee and
the Company consent to the personal jurisdiction of the state and federal courts located in
California for any action or proceeding arising from or relating to this Agreement or relating to
any arbitration in which the parties are participants.

(c) Nothing in this Section 10 modifies Employee’s at-will employment status. Either Employee
or the Company can terminate the employment relationship at any time, with or without Cause.

(d) SUBMISSION OF ANY CLAIMS ARISING OUT OF, RELATING TO, OR IN CONNECTION WITH THIS
AGREEMENT, OR THE INTERPRETATION, VALIDITY, CONSTRUCTION, PERFORMANCE, BREACH OR TERMINATION
THEREOF TO BINDING ARBITRATION, CONSTITUTES A WAIVER OF THE PARTY’S RIGHT TO A JURY TRIAL AND
RELATES TO THE RESOLUTION OF ALL DISPUTES RELATING TO ALL ASPECTS OF THE EMPLOYER/EMPLOYEE
RELATIONSHIP, INCLUDING BUT NOT LIMITED TO, THE FOLLOWING CLAIMS:

(i) ANY AND ALL CLAIMS FOR WRONGFUL DISCHARGE OF EMPLOYMENT; BREACH OF CONTRACT, BOTH EXPRESS
AND IMPLIED; BREACH OF THE COVENANT OF GOOD FAITH AND FAIR DEALING, BOTH EXPRESS AND IMPLIED;
NEGLIGENT OR INTENTIONAL INFLICTION OF EMOTIONAL DISTRESS; NEGLIGENT OR INTENTIONAL
MISREPRESENTATION; NEGLIGENT OR INTENTIONAL INTERFERENCE WITH CONTRACT OR PROSPECTIVE ECONOMIC
ADVANTAGE; AND DEFAMATION;

(ii) ANY AND ALL CLAIMS FOR VIOLATION OF ANY FEDERAL STATE OR MUNICIPAL STATUTE, INCLUDING,
BUT NOT LIMITED TO, TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, THE CIVIL RIGHTS ACT OF 1991, THE
AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, THE AMERICANS WITH DISABILITIES ACT OF 1990, THE
FAIR LABOR STANDARDS ACT, THE CALIFORNIA FAIR EMPLOYMENT AND HOUSING ACT, AND LABOR CODE SECTION
201, et seq; and

(iii) ANY AND ALL CLAIMS ARISING OUT OF ANY OTHER LAWS AND REGULATIONS RELATING TO EMPLOYMENT
OR EMPLOYMENT DISCRIMINATION.

 

 

 

11. Accrued Obligation. The Company’s obligations under this Agreement, including its
obligations pursuant to Section 2, shall accrue and be owing as of the Effective Date and the
rights of Employee hereunder shall vest immediately but remain contingent and conditioned on the
occurrence of an Involuntary Termination and Employee delivering (and not revoking) a release of
claims as required under Section 8. For clarity, the Company shall treat its obligations hereunder
as outstanding as of the date hereof, including for purposes of determining its insolvency, and the
Company’s obligations hereunder shall be due and payable regardless of any subsequent insolvency of
the Company.

12. Definition of Terms. The following terms referred to in this Agreement shall have
the following meanings:

(a) Cause. “Cause” shall mean (i) any act of personal dishonesty taken by Employee in
connection with his or her responsibilities as an employee which is intended to result in
substantial personal enrichment of Employee, (ii) Employee’s conviction of a felony that the Board
reasonably believes has had or will have a material detrimental effect on the Company’s reputation
or business, (iii) a willful act by Employee that constitutes misconduct and is injurious to the
Company, or (iv) continued willful violations by Employee of Employee’s obligations to the Company
after there has been delivered to Employee a written demand for performance from the Company that
describes the basis for the Company’s belief that Employee has not substantially performed his or
her duties.

(b) Involuntary Termination. “Involuntary Termination” shall mean (i) without
Employee’s express written consent, a significant reduction of Employee’s duties, position or
responsibilities relative to Employee’s duties, position or responsibilities in effect immediately
prior to such reduction, or the removal of Employee from such position, duties and
responsibilities; (ii) without Employee’s express written consent, a material reduction by the
Company of Employee’s base salary as in effect immediately prior to such reduction; (iii) without
Employee’s express written consent, a material reduction by the Company in the kind or level of
employee benefits (including cash and stock bonus plans) to which Employee is entitled immediately
prior to such reduction which results in a material adverse change to Employee’s employment
relationship; (iv) without Employee’s express written consent, the relocation of Employee to a
facility or a location that results in an increase in Employee’s one-way commute from Employee’s
residence immediately prior to such relocation by more than fifty (50) miles; (v) any purported
termination of Employee by the Company which is not effected for Cause; or (vi) a material breach
of this Agreement by the Company, including, but not limited to the failure
of the Company to obtain the assumption of this Agreement by any successors contemplated in
Section 7.

(c) Severance Payment. “Severance Payment” shall mean Employee’s then-current base
salary multiplied by a fraction, the numerator of which is the number of calendar days between the
Termination Date and June 30, 2009 (not including the Termination Date but including June 30, 2009)
and the demonitator of which is 365.

(d) Termination Date. “Termination Date” shall mean the date specified in a notice of
termination as contemplated under Section 9(b).

 

 

 

13. Miscellaneous Provisions.

(a) Amendment or Termination. The Board may in its sole discretion amend or terminate
this Agreement at any time and in any manner; provided, however, that the Board may not
terminate or amend this Agreement in a way that is materially adverse to Employee without the
written consent of Employee; provided further that notwithstanding anything to the contrary
contained in this paragraph or in this Agreement, it is the parties’ intent that no payment made or
to be made hereunder shall be subject to the provisions of Section 409A(a)(1)(B) of the Internal
Revenue Code, as amended, and accordingly, the parties agree that this Agreement and Employee’s
rights under it shall be amended to conform to their intent as set forth in this proviso.

(b) Effect of Statutory Benefits. To the extent that any severance benefits are
required to be paid to Employee upon termination of employment with the Company as a result of any
requirement of law or any governmental entity in any applicable jurisdiction, the aggregate amount
of severance benefits payable pursuant to Section 2 shall be reduced by such amount.

(c) No Duty to Mitigate. Employee shall not be required to mitigate the amount of any
payment contemplated by this Agreement, nor shall any such payment be reduced by any earnings that
Employee may receive from any other source.

(d) Waiver. No provision of this Agreement may be waived or discharged unless the
waiver or discharge is agreed to in writing and signed by Employee and by an authorized officer of
the Company (other than Employee). No waiver by either party of any breach of, or of compliance
with, any condition or provision of this Agreement by the other party shall be considered a waiver
of any other condition or provision or of the same condition or provision at another time.

(e) Integration. This Agreement supersedes all prior or contemporaneous agreements,
whether written or oral, with respect to this Agreement; provided, however, that, for
clarification purposes, this Agreement shall not affect any agreements between the Company and
Employee regarding intellectual property matters, non-solicitation restrictions or confidential
information of the Company. In addition, except as set forth in Sections 3 and 6, nothing in this
Agreement shall be construed as impacting any equity award granted to an employee.

(f) Choice of Law. The validity, interpretation, construction and performance of this
Agreement shall be governed by the internal substantive laws, but not the conflicts of law rules,
of the State of California as applied to agreements among California residents entered into and to
be performed entirely within California.

(g) Severability. The invalidity or unenforceability of any provision or provisions
of this Agreement shall not affect the validity or enforceability of any other provision hereof,
which shall remain in full force and effect.

 

 

 

(h) Employment Taxes. Employee is responsible for any applicable taxes of any nature
(including any penalties or interest that may apply to such taxes) that the Company reasonably
determines apply to any payment made hereunder. Employee’s receipt of any benefit hereunder is
conditioned on his or her satisfaction of any applicable withholding or similar obligations that
apply to such benefit, and any cash payment owed hereunder will be reduced to satisfy any such
withholding or similar obligations that may apply.

(i) Section 409A of the Code.

(i) This Agreement is intended to comply with, or otherwise be exempt from, Section 409A of
the Code and any regulations and Treasury guidance promulgated thereunder. The Company shall
undertake to administer, interpret, and construe this Agreement in a manner that does not result in
the imposition on an employee of any additional tax, penalty, or interest under Section 409A of the
Code. If the Company determines in good faith that any provision of this Agreement would cause
employees to incur an additional tax, penalty, or interest under Section 409A of the Code, the
Board may, without the consent of any employee, amend this Agreement as may be necessary to ensure
compliance with the distribution provisions of Section 409A of the Code or as otherwise needed to
ensure that this Agreement complies with Section 409A of the Code. The preceding provisions,
however, shall not be construed as a guarantee by the Company of any particular tax effect to an
employee under this Agreement. The Company shall not be liable to any employee for any payment
made under this Agreement that is determined to result in an additional tax, penalty, or interest
under Section 409A of the Code, nor for reporting in good faith any payment made under this
Agreement as an amount includible in gross income under Section 409A of the Code.

(ii) “Termination of employment,” “resignation,” or words of similar import, as used in this
Agreement, mean, for purposes of any payments under this Agreement that are payments of deferred
compensation subject to Section 409A of the Code, the employee’s “separation from service” as
defined in Section 409A of the Code.

(iii) If a payment obligation under this Agreement arises on account of the employee’s
separation from service while the employee is a “specified employee” (as defined under Section 409A
of the Code and determined in good faith by the Company), any payment of “deferred compensation”
(as defined under Treasury Regulation Section 1.409A-1(b)(1), after giving effect to the exemptions
in Treasury Regulation Sections 1.409A-1(b)(3) through (b)(12)) that is scheduled to be paid within
six (6) months after such separation from service shall accrue
without interest and shall be paid within 15 days after the end of the six-month period
beginning on the date of such separation from service or, if earlier, within 15 days after his or
her death.

 

 

 

The parties have executed this Retention and Incentive Agreement as of the Effective Date.

	 	 	 	 	 	 	 
	COMPANY:	 	ADVENTRX PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Patrick Keran
 

Name: Patrick Keran
	 	 
	 

	 	 	 	Title:   Vice President, Legal	 	 
	 
	 	 	 	 	 	 
	EMPLOYEE:	 	/s/ Michele L. Yelmene	 	 
	 	 	 	 	 
	 	 	Michele L. Yelmene	 	 

 

 

 

Exhibit A

NOTICE OF GRANT OF RESTRICTED STOCK UNITS

(including Restricted Stock Units Agreement)

 

 

 

ADVENTRX PHARMACEUTICALS, INC.

NOTICE OF GRANT OF RESTRICTED STOCK UNITS

The Participant has been granted an award of Restricted Stock Units (the
“Award”) pursuant to the ADVENTRX Pharmaceuticals, Inc. 2008 Omnibus Incentive Plan (the
“Plan”), each of which
represents the right to receive on the Settlement Date (described below) one (1) share of common
stock of ADVENTRX Pharmaceuticals, Inc., par value $0.001 per share, as follows:

	 	 	 
	Participant:
	 	Michele L. Yelmene

	 	 	 

	Grant Date:
	 	January 30, 2009

	 	 	 

	Number of Restricted
Stock Units:
	 	450,000, subject to adjustment as
provided by the Restricted Stock Units
Agreement.

	 	 	 

	Settlement Date:
	 	For each Restricted Stock Unit, except
as otherwise provided by the
Restricted Stock Units Agreement, the
date on which the units become Vested
Units in accordance with the vesting
schedule set forth below.

	 	 	 

	Vested Units:
	 	Except as provided by the Restricted
Stock Units Agreement and provided
that the Participant’s Services have
not terminated prior to the
consummation of a Strategic
Transaction (as defined below), one
hundred percent (100%) of the
Restricted Stock Units shall vest
immediately prior to the consummation
of a Strategic Transaction.

A “Strategic Transaction” shall mean: (a) any transaction or series of related transactions or
any plan (including, without limitation, any reorganization, merger, consolidation, exchange or
sale of stock or other securities) in which the stockholders of the Company as constituted
immediately prior to the consummation of such transaction, transactions or plan will, immediately
after the consummation of such transaction, transactions or plan and as a result of securities
issued as consideration for such transaction, transactions or plan, fail to hold at least 50% of
the outstanding voting capital stock of the resulting or surviving entity (or its parent if the
surviving entity is wholly owned by such parent entity); (b) any transaction or series of related
transactions or any plan (including, without limitation, any reorganization, merger, consolidation,
exchange or sale of stock or other securities) in which the stockholders of a subsidiary of the
Company as constituted immediately prior to the consummation of such transaction, transactions
or plan (including a wholly-owned subsidiary) will, immediately after the consummation of such
transaction, transactions or plan and as a result of securities issued as consideration for such
transaction, transactions or plan, fail to hold at least 50% of the outstanding voting capital
stock of the resulting or surviving entity (or its parent if the surviving entity is wholly owned
by such parent entity); (c) a sale, transfer, lease or other disposition by means of any
transaction or series of related transactions or any plan of all or substantially all of the assets
of the Company; (d) the assignment, transfer, lease, sale or other disposition by means of any
transaction or series of related transactions or any plan of all or substantially all of the assets
of one or more subsidiaries of the Company, the assets of which constitute all or substantially all
of the assets of the Company and its subsidiaries taken as a whole; (e) the grant of, among other
things, an exclusive license under the Company’s patents and patent applications related to ANX-514
to make, use or sell products covered by such patents and patent applications in the United States
for the treatment of cancer by intravenous administration of formulations consisting of emulsified
products; and (f) any transaction that the Board or the Committee determines constitutes a
“Strategic Transaction.”

 

 

 

By their signatures below or by electronic acceptance or authentication in a form authorized
by the Company, the Company and the Participant agree that the Award is governed by this Notice and
by the provisions of the Plan and the Restricted Stock Units Agreement, both of which are made a
part of this document. The Participant represents that the Participant has read and is familiar
with the provisions of the Plan and Restricted Stock Units Agreement, and hereby accepts the Award
subject to all of their respective terms and conditions.

	 	 	 	 	 	 	 	 	 	 	 
	ADVENTRX PHARMACEUTICALS, INC.	 	 	 	PARTICIPANT	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:
	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 
	 
	Its: 	Vice President, Legal	 	 	 	Signature	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 

Date
	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Address:	6725 Mesa Ridge Rd., Suite 100	 	 	 	 	 	 
	 

	 	 	San Diego, CA 92121
	 	 	 	 

	 	 
	 

	 	 	 	 	 	 	 	 

	 	 

	 	 	 
	ATTACHMENTS:

	 	2008 Omnibus Incentive Plan, as amended to the Grant Date

Restricted Stock Units Agreement 

Plan Prospectus

 

2Exhibit 10.8

EXHIBIT 10.8

LICENSE AGREEMENT

THIS LICENSE AGREEMENT (“Agreement”) dated as of March 25, 2009 (“Effective
Date”), is entered into among ADVENTRX Pharmaceuticals, Inc., a Delaware corporation, having
its principal place of business at 6725 Mesa Ridge Road, Suite 100, San Diego, California, USA
92121 (“ADVENTRX”), SD Pharmaceuticals, Inc., a Delaware corporation and wholly-owned
subsidiary of ADVENTRX (“SDP”), and Shin Poong Pharmaceutical Co., Ltd., a company
organized under the laws of Republic of Korea, having its principal place of business at 748-31,
Yoksam-Dong, Kangnam-Ku, Seoul, Korea 135-925(“Licensee”).

BACKGROUND

A. SDP owns certain patent rights related to a pharmaceutical product candidate known as
ANX-514, which SDP acquired pursuant to a License Agreement, dated December 10, 2005, with Latitude
Pharmaceuticals, Inc. (“LPI”) and Andrew X. Chen (the “LPI Agreement”), a true and
complete copy of which has been delivered to Licensee, pursuant to which LPI has certain rights
with respect to patent prosecution and maintenance and patent enforcement.

B. Licensee desires to receive a license to such patent rights and certain related know-how
for the territory of South Korea upon the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein
contained, and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Parties (defined below) hereby agree as follows:

ARTICLE 1

DEFINITIONS

For purposes of this Agreement, the following terms when used with initial capital letters
shall have the respective meanings set forth below in this Article 1 or elsewhere herein.

1.1 “Adverse Event” means any untoward medical occurrence in a patient or subject who
is administered a Product, whether or not considered related to a Product, including, without
limitation, any undesirable sign (including abnormal laboratory findings of clinical concern),
symptom or disease temporally associated with the use of such Product.

1.2 “Affiliate” of a Party means any person, corporation, or other business entity
which, directly or indirectly through one or more intermediaries, controls, is controlled by, or is
under common control with such Party, as the case may be. As used in this paragraph,
“control” means: (a) to possess, directly or indirectly, the power to affirmatively direct
the management and policies of such person, corporation, or other business entity, whether through
ownership of voting securities or by contract relating to voting rights or corporate governance; or
(b) direct or indirect beneficial ownership of fifty percent (50%) or more of the voting share
capital in such person, corporation, or other business entity.

1.3 “ADVENTRX Know–How” means the physical embodiment, to the extent available, of any
proprietary information or materials related to the manufacture, preparation, formulation, use or
development of Products owned by ADVENTRX or SDP that were used or generated in connection with the
development or manufacture of ANX-514.

 

 

 

1.4 “ADVENTRX Patents” means the patents and patent applications listed on Exhibit
A attached to this Agreement, together with any patents issuing therefrom and all additions,
divisionals, continuations, continuations-in-part (only to the extent of the claims therein that
are entitled to the priority date of the listed patent applications), substitutions, reissues,
re-examinations, extensions, registrations, patent term extensions, Supplemental Protection
Certificates, and renewals of any of the foregoing.

1.5 “ADVENTRX Technology” means the ADVENTRX Patents and/or the ADVENTRX Know-How.

1.6 “Bioequivalence” means the absence of a significant difference in the rate and
extent to which the active pharmaceutical ingredient (API) or active moiety in a pharmaceutical
drug compound becomes available at the site of drug action when administered at the same molar dose
under similar conditions.

1.7 “FDA” means the United States Food and Drug Administration, or any successor
entity thereto performing similar functions.

1.8 “Field” means the treatment of cancer by intravenous administration of
formulations of docetaxel as emulsified products.

1.9 “First Commercial Sale” means the first sale of Product in the Territory following
receipt of Regulatory Approval.

1.10 “KFDA” means the Korea Food and Drug Administration, or any successor entity
performing similar functions.

1.11 “NDA” means a new drug application filed with the FDA pursuant to 21 C.F.R.
Sec.314, seeking permission to market a product in interstate commerce in the United States.

1.12 “Net Sales” means the aggregate gross sales price invoiced or otherwise received
(whichever is greater) by Licensee, its Affiliates, or Sublicensees, from sales or other
dispositions of all Products to Third Party customers, less reasonable and customary deductions for
the following items incurred with respect to the sale to such customers: (a) credits, allowances,
discounts, rebates and charge backs to the customer (including those granted to managed-care
entities and government agencies as well as entities that manage patient drug benefits), to the
extent actually taken by the customer; (b) freight, postage and insurance costs on shipments to the
customer (to the extent included in the gross sales price); (c) trade, quantity or cash discounts
allowed to and actually taken by the customer on the sale; and (d) sales, value-added and other
direct taxes (including customs, duties and other similar governmental charges) incurred by the
seller on the sale, other than franchise or income tax of any kind whatsoever. If a sale or other
disposition with respect to Products is not at arm’s length, then the Net Sales from such sale or
other disposition shall be the arm’s length fair market value of the Product, which will mean
Licensee’s, its Affiliate’s, or Sublicensee’s, as applicable, average sales price in arm’s length
sales of such Product for the calendar year in the country in which the sale took place.

1.13 “NHI Price” means the national health insurance price for a unit of Product set
by the Health Insurance Review Agency (HIRA).

1.14 “Party” means any of ADVENTRX, SDP or Licensee individually and “Parties”
means ADVENTRX, SDP and Licensee collectively. Except as otherwise expressly set forth in this
Agreement, references to “either Party”, “the other Party” and the like, shall mean either (i)
Licensee or (ii) ADVENTRX and SDP, as the case may be.

 

2

 

1.15 “Product” means any one or more of (i) the pharmaceutical product candidate known
as ANX-514 (docetaxel emulsion) or any improvement or derivative thereof, or (ii) any product for
which the manufacture, use, sale or importation is covered by a Valid Claim of the ADVENTRX
Patents.

1.16 “Regulatory Approval” means: (a) in the United States, written notice of
marketing approval by the FDA for a pharmaceutical or biological therapeutic product, and (b) in
any other country, written notice of all approvals by each Regulatory Authority (other than the
FDA).

1.17 “Regulatory Authority” means the FDA or any regulatory body with similar
regulatory authority (including the KFDA) in any other jurisdiction together with, as applicable,
any other regulatory body with authority in such other jurisdiction over advertising, promoting,
marketing, selling and other commercial activities related to a pharmaceutical or biological
therapeutic product (including any pricing, reimbursement and similar determinations and
post-approval monitoring and safety matters related to the foregoing).

1.18 “Right of Reference” means a “Right of Reference,” as that term is defined in
Title 21, Section 314.3(b) of the United States Code of Federal Regulations, and any comparable
right existing under the laws or regulations of any other country.

1.19 “Serious Adverse Event” means any event at any dose that results in any of the
following outcomes: death, a life-threatening Adverse Event, in patient hospitalization or
prolongation of existing hospitalization, a persistent or significant disability or incapacity, or
a congenital anomaly or birth defect. Important medical events that may not result in death, be
life threatening, or require hospitalization may be considered a Serious Adverse Event when, based
upon appropriate medical judgment, they may jeopardize the patient or subject, and may require
medical or surgical intervention to prevent one of the outcomes listed in this definition.

1.20 “Sublicensee” means a Third Party to whom Licensee or an Affiliate of Licensee
grants, in accordance with Section 2.4, a sublicense to one or more Products under the ADVENTRX
Technology, as well as any person, corporation or other entity to whom a sublicense is granted by
such a Third Party.

1.21 “Sublicense Revenue” means all cash payments, the fair market cash value of any
equity consideration (less any amounts paid for such equity consideration), and forgivable loans
(to the extent actually forgiven) received by Licensee, its Affiliates, or Sublicensees from a
Third Party in consideration for the grant of a sublicense under the ADVENTRX Technology, including
any upfront payments, license maintenance fees, milestone payments or the like. Sublicense Revenue
will not include: (a) in the event that Licensee collaborates on research and/or development with
such a Sublicensee after the effective date of the sublicense agreement, amounts paid by such
Sublicensee as bona fide reimbursement for research and development costs (not to exceed
fully-allocated costs plus thirty percent (30%)) incurred after the date of such agreement;
(b) bona fide, non-forgivable loans (and forgivable loans unless and until forgiven); and (c) 
running royalties (including any amounts paid based upon sales of a Product).

1.22 “Supplementary Protection Certificate” means, with respect to Switzerland or any
jurisdiction within the European Union or European Free Trade Association, a certificate extending
exclusive rights (following the expiration of applicable patents) with respect to a medicinal
product, pursuant to Council Regulation (EEC) No. 1768/92 of 18th June 1992, and any equivalent
extension of exclusive rights in a medicinal product in any other jurisdiction in the world.

1.23 “Territory” means South Korea.

 

3

 

1.24 “Third Party” means any person, corporation, or other entity, other than
Licensee, ADVENTRX, SDP and their respective Affiliates. In the event Licensee or an Affiliate of
Licensee has granted to a Third Party, in accordance with Section 2.4, a sublicense to one or more
Products under the ADVENTRX Technology, and such Third Party further grants a sublicense to one or
more Products under the ADVENTRX Technology to another person, corporation, or other entity, “Third
Party” includes any person, corporation, or other entity other than such Third Party and its
Affiliates.

1.25 “Valid Claim” means a pending or issued claim of a patent or patent application
within the ADVENTRX Patents which: (a) has not been held invalid by a court or other government
agency of competent jurisdiction in a decision from which no appeal can or has been taken; and
(b) has not expired or been cancelled, withdrawn or abandoned. With respect to a Valid Claim of a
pending patent application, the phrase to “infringe a Valid Claim” means to engage in an activity
that would infringe (i.e., by either directly infringing, contributorily infringing, or inducing
infringement of) such Valid Claim if it were contained in an issued patent. With respect to any
jurisdiction in which a Supplementary Protection Certificate is in existence that provides
exclusivity substantially similar in scope to a Valid Claim that has expired in such jurisdiction,
a Valid Claim shall be deemed to exist in such jurisdiction for the life of such Supplementary
Protection Certificate.

1.26 Additional Definitions. Each of the following terms shall have the meaning
described in the corresponding section of this Agreement indicated below:

	 	 	 	 	 
	Term	 	Section Defined	 
	 
	Agreement
	 	 	Introduction
	ADVENTRX
	 	 	Introduction
	ADVENTRX Indemnitees
	 	 	14.1	 
	Contract Manufacturer
	 	 	9.1	 
	Controlling Party
	 	 	11.5(c)	
	Disclosing Party
	 	 	10.1	 
	Effective Date
	 	 	Introduction
	Infringement
	 	 	11.5(a)	
	Infringement Action
	 	 	11.5(c)	
	Liabilities
	 	 	14.1	 
	Minimum Annual Royalty Payment
	 	 	5.5	 
	Proprietary Information
	 	 	10.1	 
	Recipient
	 	 	10.1	 
	Requested Supply
	 	 	9.3	 
	Licensee
	 	 	Introduction
	Licensee Indemnitees
	 	 	14.2	 
	LPI
	 	 	Introduction
	LPI Agreement
	 	 	Introduction

 

4

 

ARTICLE 2

GRANT OF LICENSE

2.1 Exclusive License. Subject to Licensee’s compliance with the terms and conditions
of this Agreement, SDP hereby grants to Licensee an exclusive, non-transferable (except in
accordance with Section 15.2) license, under the ADVENTRX Patents, including the right to
sublicense in accordance with Sections 2.3 and 2.4, to research, develop, make, have made, use,
offer for sale, sell and import Products, in each case solely within the Field and within the
Territory.

2.2 Non-exclusive License. Subject to Licensee’s compliance with the terms and
conditions of this Agreement, ADVENTRX and SDP hereby grant to Licensee a non-exclusive,
non-transferable (except as provided in Section 15.2) license, under the ADVENTRX Know-How,
including the right to sublicense in accordance with Sections 2.3 and 2.4, to research, develop,
make, have made, use, offer for sale, sell and import Products, in each case solely within the
Field and within the Territory.

2.3 Extension of License to Affiliates. Licensee may extend its rights under the
licenses granted in Sections 2.1 and 2.2 to one or more of its Affiliates; provided that Licensee
shall remain responsible for such Affiliate’s compliance with all obligations under this Agreement
applicable to such Affiliate, and any action by an Affiliate that would, if conducted by Licensee,
be a breach of this Agreement by Licensee shall be deemed to be a breach of this Agreement by
Licensee.

2.4 Sublicenses.

(a) Right to Grant Sublicenses; Sublicense Revenue. Subject to the terms and
conditions of this Section 2.4, Licensee shall have the right to grant and authorize sublicenses
under the rights granted in Sections 2.1 and 2.2 above.

(b) Other Sublicense Requirements. Licensee may not sublicense any rights under the
ADVENTRX Technology without the prior written consent of ADVENTRX, which consent shall not be
unreasonably withheld. Any sublicense (i) shall not conflict with, and shall be subordinate to, the
terms and conditions of this Agreement, and (ii) shall contain provisions at least as protective of
ADVENTRX, SDP and their Affiliates as the provisions in this Agreement related to confidentiality,
intellectual property, auditing, product labeling, effect of termination, indemnification and
insurance. Licensee shall be responsible for all actions of Sublicensees and shall remain
responsible to ADVENTRX for any royalties and other payments under this Agreement. For the
avoidance of doubt, the foregoing shall apply to sublicenses granted to an alleged infringer as
contemplated by Section 11.5.

2.5 No Other Rights. No license, either express or implied, is granted hereunder with
respect to any patent, trade secret, know-how, other information or intellectual property rights of
ADVENTRX or SDP except as expressly stated above in this Agreement.

ARTICLE 3

TECHNOLOGY TRANSFER

ADVENTRX shall provide its reasonable assistance to provide to Licensee the ADVENTRX Know-How
listed on Exhibit B. For the avoidance of doubt, ADVENTRX will retain ownership and be
entitled to retain copies of all such items. ADVENTRX will use good faith efforts to provide
answers to specific questions during normal business hours to assist Licensee in understanding and
implementing such ADVENTRX Know-How from time to time. Neither ADVENTRX nor SDP shall have any
responsibility for any modification of, or additional support with respect to, any ADVENTRX or SDP
process, methods or materials of the ADVENTRX Know-How in order to enable or improve manufacturing
or other operations of Licensee or any Third Party. ADVENTRX and SDP may, from time to time,
supplement or revise the ADVENTRX Know-How but shall have no obligation to provide any such
supplements or revisions to Licensee. ADVENTRX shall make ADVENTRX Know-How specifically relevant
to the manufacture of Products that it develops and provides to the Contract Manufacturer,
available for use by Contract Manufacturer on Licensee’s behalf in accordance with Article 9.

 

5

 

ARTICLE 4

DILIGENCE

4.1 Diligence.

(a) Licensee shall use reasonable best efforts to (i) pursue and achieve all Regulatory
Approvals for Products in the Territory, and (ii) maximize Product sales in the Territory.

(b) Conduct all of the activities, and on the timelines, set forth in the Development Plan
attached hereto as Exhibit C that are applicable to Licensee.

(c) Anything to the contrary in this Agreement (including Section 8.7 or Exhibit C)
notwithstanding, Licensee’s obligations hereunder are separate and independent from ADVENTRX’s
research, development and/or commercialization activities, which ADVENTRX is free to conduct (or
not to conduct) in its discretion and without any impact on Licensee’s obligations hereunder.

4.2 Reporting. Licensee agrees to keep ADVENTRX reasonably informed as to its
development and commercialization activities with respect to Products, including by providing
prompt notification of the completion of any activities set forth on Exhibit C. Without
limiting the foregoing, Licensee shall provide ADVENTRX with written reports no less frequently
than biannually summarizing Licensee’s efforts to develop and commercialize Products hereunder,
which reports shall include out-of-pocket and fully-burdened costs and expenses associated with
such activities.

4.3 Meetings. ADVENTRX and Licensee shall meet, by teleconference, video conference,
or in-person, to discuss the state of the development and commercialization activities. At
ADVENTRX’s request, but no more frequently than annually, the ADVENTRX and Licensee shall meet
in-person at ADVENTRX’s corporate headquarter.

4.4 Competitive Products. During the term of this Agreement Licensee and its
Affiliates shall not develop, take or receive a license or sublicense to, manufacture, register,
sell, promote or distribute in the Territory any docetaxel products in the Field.

ARTICLE 5

PAYMENTS AND ROYALTIES

5.1 Upfront License Fee. Within 30 days of receipt of invoice after the Effective
Date, Licensee shall pay to ADVENTRX an upfront license fee of Three Hundred Thousand US Dollars
(US $300,000). Such amount shall not be creditable or refundable.

5.2 Regulatory Milestones. Licensee shall pay to ADVENTRX the regulatory milestone
payments set out below following the first achievement by Licensee, or any of its Affiliates, or
Sublicensees, of the corresponding regulatory milestone set out below with respect to each Product
within 30 days from the date of such events:

	 	 	 	 	 
	Regulatory Milestone	 	Milestone Payment	 
	 
	Receipt of Regulatory Approval
for marketing of a Product in the Territory
	 	US $400,000

 

6

 

In the event Licensee is required by the KFDA to conduct a Bioequivalence or clinical trial in
human subjects prior to receipt of Regulatory Approval for a Product in the Territory, the
regulatory milestone payment for such Product shall be US $200,000.

5.3 Commercial Milestones. Licensee shall pay ADVENTRX the one-time commercial
milestone payments set forth below following the end of the calendar year in which the
corresponding commercial milestone for all Products is first achieved. Commercial milestone
payments are not creditable or refundable.

	 	 	 	 	 
	Annual Net Sales of Products	 	Milestone Payment	 
	 
	 	 	 	 
	US $5,000,000
	 	US $150,000
	 
	 	 	 	 
	US $10,000,000
	 	US $300,000
	 
	 	 	 	 
	US $15,000,000
	 	US $450,000
	 
	 	 	 	 
	US $20,000,000
	 	US $600,000

For the avoidance of doubt, and by way of example only, if Licensee has Net Sales of Products
of $6,000,000 in year 1, $12,000,000 in year 2 and $22,000,000 in year 3, then Licensee shall pay
commercial milestone payments of $150,000 for year 1 ($150,000 for achieving $5,000,000 in Net
Sales), $300,000 for year 2 ($300,000 for achieving $10,000,000 in Net Sales, but with no milestone
obligation for achieving $5,000,000 in Net Sales (milestone previously paid)) and $1,050,000 for
year 3 ($450,000 for achieving $15,000,000 in Net Sales and $600,000 for achieving $20,000,000 in
Net Sales, but with no milestone obligation for achieving $5,000,000 in Net Sales (milestone
previously paid) or $10,000,000 in Net Sales (milestone previously paid)).

5.4 Royalty Payments.

(a) In the event that the NHI Price is KRW 200,000 or more per 20mg vial, Licensee shall pay
to ADVENTRX the royalty of *** percent (***%) of the Net Sales of the Product.

(b) In the event that the NHI Price of the Product in the Territory is KRW 180,000 or more but
less than KRW 200,000 per 20mg vial, Licensee shall pay to ADVENTRX the royalty of *** percent
(***%) of the Net Sales of the Product.

(c) In the event that the NHI price of the Product in the Territory is KRW160,000 or more but
less than KRW180,000 per 20mg vial, Licensee shall pay to ADVENTRX the royalty of *** percent
(***%) of the Net Sales of the Product.

(d) In the event that the NHI price of the Product in the Territory is less than 160,000 per
20mg vial or no NHI price is designated, Licensee shall pay to ADVENTRX the royalty of *** percent
(***%) of the Net Sales of the Product.

	 	 	 
	***	 	Portions of this page have been omitted pursuant to a
request for Confidential Treatment filed separately with the Commission.

 

7

 

(e) Royalty Terms. 

(i) One Royalty. No more than one royalty payment shall be due under this Agreement
with respect to a sale of a particular Product (e.g., even if such Product is covered by multiple
Valid Claims).

(ii) Royalty Term. Licensee’s obligation to pay royalties under this Section 5.4
shall continue with respect to sales of a Product in a particular country until the date which is
the later of: (i) expiration of the last Valid Claim in such country that would be infringed by
the sale of such Product in the Territory; or (ii) ten (10) years after the First Commercial Sale.
Thereafter, no further royalties shall be due with respect to such Product in the Territory.

5.5 Minimum Annual Royalty Payments. Beginning with the first full calendar year
following the date that is the second anniversary of the First Commercial Sale and for each
calendar year thereafter for the duration of the royalty term set forth in Section 5.4(e)(ii), a
minimum annual royalty payment of US $100,000 (the “Minimum Annual Royalty Payment”) shall
apply. In the event the royalty payments under Section 5.4 for a calendar year is less than the
Minimum Annual Royalty Payment for such calendar year, Licensee shall, by the due date for royalty
payments for such calendar year, pay to ADVENTRX such difference. For example, if the First
Commercial Sale occurs on February 20, 2011, then the first Minimum Annual Royalty Payment shall
apply with respect to the calendar year ending December 31, 2014. Such payments shall not be
refundable or creditable.

5.6 Payments With Respect to Sublicense Revenue. In the event Licensee or its
Affiliate sublicenses under Section 2.4 (or a Third Party to whom a sublicense was previously
granted further sublicenses to another Third Party), Licensee shall pay ADVENTRX a portion of any
Sublicense Revenue resulting from corresponding agreements executed by Licensee, or an Affiliate of
Licensee or a Sublicensee within the first three (3) years after the Effective Date, as set forth
below;

(a) if such agreements are executed in the first twelve (12) months after the Effective Date,
Licensee shall pay ADVENTRX fifty percent (50%) of all Sublicense Revenue resulting from such
agreements (including any extensions, amendments and restatements thereof);

(b) if such agreements are executed in the second twelve (12) months after the Effective Date,
Licensee shall pay ADVENTRX thirty percent (30%) of all Sublicense Revenue resulting from such
agreements (including any extensions, amendments and restatements thereof), and

(c) if such agreements are executed in the third twelve (12) months after the Effective Date,
Licensee shall pay ADVENTRX ten percent (10%) of Sublicense Revenue resulting from such agreements
(including any extensions, amendments and restatements thereof).

(d) Licensee shall have no obligation to share Sublicense Revenues with ADVENTRX resulting
from any sublicense agreement executed after thirty-six (36) months after the Effective Date.

 

8

 

ARTICLE 6

PAYMENTS

6.1 Royalty and Sublicense Revenue Payment Terms. Royalties and, if applicable,
Sublicense Revenue that have accrued during the period covered by each report provided pursuant to
Section 7.1 shall be due and payable on the date such report is due.

6.2 Payment Method. Unless otherwise expressly stated in this Agreement, all amounts
specified in, and all payments to be made under, this Agreement shall be in United States Dollars
by wire transfer in immediately available funds to a U.S. account designated by ADVENTRX, or by
other mutually acceptable means. If any currency conversion shall be required in connection with
determining sales levels or the payment of any royalties, milestone payments or Sublicense Revenue
under this Agreement, such conversion shall be made by using the average of the interbank exchange
rates for the purchase and sale of United States Dollars reported by The Wall Street
Journal (U.S., Western Edition) on the last business day of the calendar year to which such
royalty, milestone or Sublicense Revenue payments relate.

6.3 Overdue Payments. In the event any amount payable by Licensee to ADVENTRX under
this Agreement is not paid when due, such outstanding payment shall accrue interest (from the date
such payment is due through and including the date upon which full payment is made) at a rate of
one and a half percent (1.5%) per month from the due date until paid in full, provided that in no
event shall said rate exceed the maximum interest rate permitted by law in regard to such payments.
Such payment when made shall be accompanied by all interest so accrued. In the event such payment
does not include all accrued interest, the payment will be applied first to amounts originally
payable and then to outstanding interest, and interest will continue to accrue on any unpaid
amounts (whether originally due or interest thereon). Said interest and the payment and acceptance
thereof shall not negate or waive the right of ADVENTRX to any other remedy, legal or equitable, to
which it may be entitled because of the delinquency of a payment.

6.4 Tax Withholding. Any sum required under applicable laws to be withheld from any
and all payments made to ADVENTRX under this Agreement shall be withheld and promptly paid to the
relevant tax authorities by Licensee (or its Affiliates, or Sublicensees, as the case may be).
Licensee shall ensure that the official tax receipts or other evidence of such payments be provided
to ADVENTRX in a timely manner and shall provide ADVENTRX upon request with such written
documentation regarding any such payment as available to Licensee relating to an application by
ADVENTRX for a foreign tax credit for such payment with the United States Internal Revenue Service.
Notwithstanding the foregoing, with respect to the upfront license fee under Section 5.1, any sum
required under the applicable laws to be withheld by Licensee will be the sole responsibility of
Licensee and all amounts owing from Licensee to ADVENTRX under that Section shall be grossed up to
account for any withholding taxes, value added taxes or other taxes, duties, tariffs, levies or
similar charges.

ARTICLE 7

REPORTS, RECORDS AND ACCOUNTING

7.1 Reports. After the first receipt by Licensee or an Affiliate of Licensee of
Sublicense Revenue pursuant to Section 5.6 or the First Commercial Sale, whichever is earlier,
Licensee shall furnish to ADVENTRX a written report for each calendar year during the term of this
Agreement showing:

(a) the aggregate gross sales and other dispositions of all Products (broken-out by Product)
sold or other disposed of by Licensee, its Affiliates and any Sublicensees during such calendar
year and the calculation of Net Sales from such amount;

(b) the applicable royalty rates and the royalties, payable in United States Dollars, which
shall have accrued under this Agreement based upon such Net Sales;

(c) the amount of any Sublicense Revenue received by Licensee or an Affiliate of Licensee or a
Sublicensee during such calendar year, if relevant;

(d) the exchange rates used in determining the amount of sales, royalties or Sublicense
Revenue, as applicable, payable in United States Dollars, as more specifically provided in
Section 6.2; and

(e) any reductions to or deductions from payments taken by Licensee in accordance with this
Agreement.

 

9

 

Reports to be provided by Licensee to ADVENTRX under this Section 7.1 shall be due
forty-five (45) days following the end of each calendar year (unless Licensee has sublicensed
rights to commercialize Products, in which event such reports shall be due within sixty (60) days
following the end of each calendar year). If for any year following the first receipt by Licensee
or an Affiliate of Licensee or a Sublicensee of Sublicense Revenue pursuant to Section 5.6 or the
First Commercial Sale, whichever is earlier, there were no Net Sales, and no Sublicense Revenues
were received by Licensee or an Affiliate of Licensee or a Sublicensee in such year, a report
stating such facts shall be due within sixty (60) days following the end of such year. A
responsible financial officer of Licensee (or that officer’s responsible designee), Licensee’s
independent accounting firm, or the head of Licensee’s internal audit committee shall certify in
writing that each report provided under this Section 7.1 is correct and complete.

7.2 Milestone Reports and Payments. Licensee shall notify ADVENTRX in writing within
forty-five (45) days after the achievement of each milestone set out in Sections 5.2 and 5.3 by
Licensee, its Affiliate or Sublicensee, and each such notice shall be accompanied by the
appropriate milestone payment.

7.3 Records. Licensee shall keep, and shall require that its Affiliates and each
Sublicensee keep, complete and accurate books of account and records in sufficient detail to enable
the amounts payable under this Agreement to be determined. Such books and records shall be kept at
the principal place of business of Licensee, its Affiliate or such Sublicensee, as the case may be,
for at least sixty (60) months following the end of the calendar year to which such books and
records pertain; provided, however, that in the event ADVENTRX conducts an audit and a dispute
arises over the accuracy of reports or payments, Licensee, its Affiliates and each Sublicensee, as
the case may be, shall retain all applicable books of account and records and continue to permit
access to such books of account and records until the resolution of such dispute.

7.4 Audits.

(a) Audit Rights. Upon reasonable prior written notice from ADVENTRX and not more
than once in each calendar year, Licensee shall permit, and shall require its Affiliates and each
Sublicensee to permit, an independent certified public accounting firm of nationally recognized
standing in the United States or the Territory selected by ADVENTRX to have access during normal
business hours to such books of account and records of Licensee, and its Affiliates and each
Sublicensee, at such person’s or entity’s principal place of business, as may be reasonably
necessary to verify the accuracy of the reports and payments provided by Licensee for any calendar
year ending not more than sixty (60) months prior to the date of such request.

(b) Audit Results. If as a result of any such audit, it is established that
additional payments were owed to ADVENTRX during the period covered by such audit pursuant to
Section 7.3(a), Licensee shall, within thirty (30) days, remit to ADVENTRX the amount of such
additional payments, together with interest on such amount, which shall be calculated pursuant to
Section 6.3. In the event such audit establishes that amounts were overpaid by Licensee during
such period, the amount of such overpayment shall be credited against future royalties and other
payments due to ADVENTRX under this Agreement. The fees charged by such accounting firm in
connection with any audit pursuant to this Section 7.3 shall be paid by ADVENTRX; provided,
however, that if a discrepancy of more than five percent (5%) of the payments due hereunder for any
calendar year within the period being audited is established, then Licensee shall within thirty
(30) days of notice of such audit results from ADVENTRX pay the fees and expenses charged by such
accounting firm in connection with such audit and such audit shall not be deemed an audit under
Section 7.3(a) for purposes of the number of audits ADVENTRX may conduct each calendar year.

(c) Confidential Financial Information. ADVENTRX shall treat all financial
information subject to review under this Article 7 as confidential, and shall cause its accounting
firm to retain all such financial information in confidence, except with respect to the enforcement
of ADVENTRX’s rights under this Agreement.

 

10

 

ARTICLE 8

REGULATORY MATTERS

8.1 ADVENTRX Matters. As between the Parties, ADVENTRX shall control all matters
related to submissions for Regulatory Approval outside of the Territory, including the conduct and
control of any preclinical and clinical studies related to any NDA submission to the FDA. ADVENTRX
and its designees may conduct and control any post-approval studies with respect to any submissions
for Regulatory Approvals outside of the Territory. For the avoidance of doubt, ADVENTRX shall have
complete authority and discretion with respect to such submissions, including the timing and
content of any submissions or whether to make any submissions, and makes no warranties as to the
results of any such submissions.

8.2 Licensee Matters. Licensee is responsible, at its expense, for all activities
required for manufacture, import, development and other testing of Products in the Territory and
for obtaining Regulatory Approval for Products in the Territory, including without limitation for
filing, obtaining and maintaining approvals for the development and commercialization of Products
in the Territory, pricing or reimbursement approvals in the Territory, and for managing all
interactions with Regulatory Authorities in the Territory. Licensee shall be responsible for
ensuring compliance with all regulatory requirements relating to Products in the Territory or in
connection with studies conducted by or on behalf of Licensee, and shall serve as the designated
regulatory official for purposes of receiving communications from relevant Regulatory Authorities.
ADVENTRX shall have the right, but not the obligation, to review and comment upon any submissions
or responses to Regulatory Authorities. LICENSEE WILL NOT CONDUCT, OR HAVE CONDUCTED, ANY CLINICAL
TRIAL FOR A PRODUCT OUTSIDE OF THE TERRITORY, WITHOUT THE PRIOR WRITTEN CONSENT OF ADVENTRX ON A
CASE-BY-CASE BASIS.

8.3 Adverse Events. Licensee shall be responsible for the surveillance, receipt and
evaluation of product complaints for Product in the Territory or in connection with any studies
conducted by or on behalf of Licensee and reporting to Regulatory Authorities regarding Adverse
Events associated therewith, including any required literature reviews. Within one hundred eighty
(180) days of the Effective Date, ADVENTRX and Licensee shall discuss and develop an agreement
containing mutually acceptable guidelines and procedures for the receipt, recordation,
communication, exchange and reporting of Adverse Events for Products. Until such time such
agreement is executed, to the extent either Party has or receives any information regarding any
Adverse Event, the Parties shall promptly forward such information as follows:

(a) Prior to First Commercial Sale, Serious Adverse Events judged by either the investigator
or sponsor of a clinical trial (or reported to a Party and judged) to be reasonably related to a
Product shall be transmitted to the other Party within three (3) calendar days from the date
received by the receiving Party; and

(b) After First Commercial Sale, Serious Adverse Events reported to a Party and judged to be
reasonably related to a Product shall be transmitted to the other Party within five (5) calendar
days from the date received by the receiving Party.

 

11

 

If to Licensee:

Facsimile:

82-2- 553-2578

Attn: Director, Regulatory Affairs

or

Overnight courier:

Director, Regulatory Affairs

Shin Poong Pharmaceutical, Co., Ltd.

748-31 Yoksam-Dong, Kangnam-Ku

Seoul 135-925 Korea

If to ADVENTRX:

Facsimile:

(858) 552-0876

Attn: Vice President, Regulatory Affairs

or

Overnight courier:

Vice President, Regulatory Affairs

ADVENTRX Pharmaceuticals, Inc.

6725 Mesa Ridge Road, Suite 100

San Diego, CA 92121

8.4 Regulatory Materials.

(a) ADVENTRX will provide to Licensee a copy of (i) all data resulting from any analytical,
stability, toxicology or pharmacokinetic work performed prior to the Effective Date relating
exclusively to a Product, and (ii) other written data, information and finalized reports (excluding
draft reports) generated prior to the Effective Date that relate exclusively to a Product, to the
extent ADVENTRX reasonably determines such information, data and reports are necessary or useful to
the preparation and submission of regulatory filings for Products within the Territory and to the
extent that such information, data and reports are in ADVENTRX’s possession and that ADVENTRX has
rights to provide such materials to Licensee. All such material will be provided in its original
format and language. ADVENTRX shall retain ownership of all of such materials. ADVENTRX hereby
grants Licensee, its Affiliates, and permitted Sublicensees a Right of Reference to the foregoing
for purposes of making regulatory filings in the Territory.

(b) Licensee shall permit ADVENTRX to access (and will ensure that its Affiliates and each
Sublicensee permit ADVENTRX to access) (i) any clinical protocol, study, clinical data or result
used in or resulting from any clinical trial of any Product, including any underlying raw data, and
(ii) any investigational new drug application (or comparable application in the Territory),
application(s) for Regulatory Approval, Regulatory Approval(s) and other regulatory filings
regarding any Product, and any regulatory communications associated with any of the foregoing.
Licensee hereby grants ADVENTRX and its Affiliates a Right of Reference to the foregoing for
purposes of making regulatory filings outside the Territory.

 

12

 

8.5 Regulatory Interactions for Product.

(a) Subject to Section 8.3, each Party shall promptly, but in any event within five (5)
business days, (i) provide to the other Party copies of any material documents or correspondence
received from any Regulatory Authority related to development and commercial activities for a
Product and (ii) inform the other Party of any inspections, proposed regulatory actions,
investigations or requests for information or a meeting by any Regulatory Authority with respect to
a Product.

(b) Licensee shall have responsibility for any recall, market withdrawals or other corrective
actions related to Products in the Territory or in connection with studies conducted by or on
behalf of Licensee and costs associated therewith; provided, however, that Licensee shall
immediately notify ADVENTRX of any consideration for the recall or withdrawal of or other action
with respect to a Product in the Territory or such a study and shall consult with ADVENTRX prior to
taking any actions with respect thereto.

(c) Subject to Section 8.3, each Party shall provide the other Party with notice of
notification or other information it receives (directly or indirectly) from any Regulatory
Authority that (i) raises any material concerns regarding the safety or efficacy of a Product; (ii)
indicates or suggests a claim of a Third Party arising in connection with a Product, or (iii) is
reasonably likely to lead to a recall or market withdrawal of a Product; provided that neither
Party shall be obliged to disclose information in breach of any contractual restriction which it
could not reasonably have avoided or which disclosure would waive any legal privilege.

8.6 Ownership. All Regulatory Approvals relating to Products labeled for use in the
Field shall be the property of ADVENTRX or its designee and held in the name of ADVENTRX or its
designee, except that Regulatory Approvals in the Territory for Products labeled for use in the
Field shall be the property of Licensee and held in the name of Licensee or its designee. Upon the
request of ADVENTRX upon or following the termination of this Agreement, Licensee shall, at its own
expense, promptly take whatever steps are necessary to transition and assign any existing
Regulatory Approvals and related filings to ADVENTRX.

8.7 Initial Product. ANX-514 manufactured from anhydrous docetaxel will be the initial
Product for which a New Drug Application for Regulatory Approval in the United States is submitted.

ARTICLE 9

SUPPLY AND MANUFACTURE

9.1 Contract Manufacturer. ADVENTRX is or was (at least as recently as March 5, 2009)
a party to a contract with *** (“Contract Manufacturer”) for certain services
related to, among other things, the supply of unlabeled and/or labeled vials of finished drug
product consisting of ANX-514 to ADVENTRX or its designee. As of March 5, 2009, Contract
Manufacturer has communicated with ADVENTRX that it would be willing to use good faith efforts to
enter into a contract with Licensee for the manufacture and supply of Product, and has delivered to
ADVENTRX the letter attached hereto as Exhibit D. Licensee may enter into negotiations
with Contract Manufacturer for the manufacture and supply of Products. ADVENTRX may, but has no
obligation to, assist Licensee in such contract negotiations, and Licensee acknowledges that
ADVENTRX shall not be required to conduct any activities in violation of its current or any future
contract with Contract Manufacturer; provided, however, that ADVENTRX shall have no responsibility
for the outcome of any negotiations between Licensee and Contract Manufacturer. EXCEPT AS
EXPRESSLY SET FORTH BELOW IN SECTION 9.2, ADVENTRX SHALL HAVE NO OBLIGATIONS OR LIABILITY WITH
RESPECT TO THE SUPPLY, MANUFACTURE, TESTING, FINISHING, PACKAGING OR LABELING OF PRODUCTS FOR THE
TERRITORY. Licensee agrees that ADVENTRX may, at any time, elect to utilize entities other than
Contract Manufacturer to manufacture Products.

	 	 	 
	***	 	Portions of this page have been omitted pursuant to a
request for Confidential Treatment filed separately with the Commission.

 

13

 

9.2 Transfer to Contract Manufacturer. ADVENTRX has provided to Contract
Manufacturer, among other things, the following items as they relate to ANX-514:

• a list components and composition, including drug substance and bulk product for
characterization purposes;

• a description of the manufacturing process, including a redacted batch record and
reports regarding lyophilization;

• product and component specifications, including release specifications; and

• information regarding the container closure system (collectively, “Manufacturing
Items”)

During the term of this Agreement, ADVENTRX agrees that it shall permit Contract Manufacturer
to utilize the Manufacturing Items in connection with the manufacture of Product for Licensee. AS
BETWEEN ADVENTRX AND LICENSEE, THE MANUFACTURING ITEMS ARE PROVIDED “AS IS” AND WITHOUT ANY
WARRANTIES.

9.3 Clinical Supply. In the event Licensee is required by the KFDA to
conduct a Bioequivalence or clinical trial in human subjects prior to receipt of Regulatory
Approval for a Product consisting of ANX-514 in the Territory, Licensee shall notify ADVENTRX of
such requirement and specify the volume of such Product in finished form that Licensee requires for
such trial; provided, however, that such requested volume of Product may not exceed the lesser of
(i) Licensee’s actual requirements for such trial, or (ii) the volume reasonably necessary to
properly conduct a single-dose, 45-subject, pharmacokinetic Bioequivalence study in humans for such
Product (such lesser amount, the “Requested Supply”). Within fifteen (15) business days of
receipt of such notice, ADVENTRX shall respond in writing to Licensee that it will (i) supply such
quantity of such Product for Licensee’s trial, or (ii) provide a refund equal to US $100,000.

9.4 Specifications. In the event ADVENTRX elects to supply the Requested Supply under
Section 9.3, ADVENTRX will deliver to Licensee with the Requested Supply, or each batch thereof, a
true, accurate and complete copy of the certificate of analysis (CoA) that it receives from the
manufacturer of such Requested Supply, and will pass-through to Licensee warranties from the
manufacturer with respect to such Requested Supply that ADVENTRX is permitted to pass-through.
Such Requested Supply shall be delivered ex works (manufacturer’s facility, or if stored by or on
behalf of ADVENTRX, such storage facility). EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS
SECTION 9.4, THE REQUESTED SUPPLY IS PROVIDED ON AN “AS IS” BASIS. Without limiting the foregoing,
Licensee shall be responsible for proper release testing of the Requested Supply and compliance
with all applicable laws and instructions of Regulatory Authorities with respect to Licensee’s (or
its Affiliates or contractor’s) receipt and use of the Requested Supply.

 

14

 

ARTICLE 10

CONFIDENTIALITY

10.1 Proprietary Information. Except as otherwise provided in this Article 10, during
the term of this Agreement and for a period of seven (7) years thereafter, each Party (the
“Recipient”) shall maintain in confidence and use only for purposes of this Agreement any
confidential information, data and materials supplied to such Party by the other Party (the
“Disclosing Party”) under this Agreement; provided that, unless the confidentiality of any
information, data or materials is expressly provided for in this Agreement, if any such
information, data or materials are in tangible form, they are marked “Confidential” or
“Proprietary,” or if disclosed orally, they are identified as confidential or proprietary when
disclosed and are confirmed in writing as confidential or proprietary within thirty (30) days
following such disclosure (such information, data and materials so disclosed, collectively
“Proprietary Information”). The ADVENTRX Know-How and any unpublished patent application
within the ADVENTRX Patents shall be deemed to be the Proprietary Information of ADVENTRX without
regard to the foregoing marking requirements, and without limiting or in any way affecting the
licenses set forth in Article 2. The obligations of the Recipient under this Article 10 not to
disclose or use Proprietary Information received from the Disclosing Party shall not apply,
however, to the extent that any such information, data or materials:

(a) are or become generally available to the public, or otherwise part of the public domain,
other than by acts or omissions of the Recipient in breach of this Agreement;

(b) are disclosed to the Recipient, other than under an obligation of confidentiality, by a
Third Party who had no obligation to the Disclosing Party not to disclose such information to
others;

(c) were already rightfully in the possession of the Recipient, other than under an obligation
of confidentiality, prior to disclosure by the Disclosing Party, as shown by Recipient’s written
records existing prior to such disclosure; or

(d) are subsequently and independently developed by the Recipient without use of, or reference
to, the Proprietary Information of the Disclosing Party, as shown by written records prepared
contemporaneously with such disclosure.

10.2 Permitted Disclosures. To the extent it is reasonably necessary or appropriate
to fulfill its obligations or exercise its rights under this Agreement:

(a) Recipient may disclose Proprietary Information which it is otherwise obligated under this
Article 10 not to disclose, to its legal advisers who are subject to a duty of confidentiality to
the Recipient, to its Affiliates, and, in each case whether actual or potential, to: Sublicensees
or other collaboration partners, assignees, contractors (including without limitation manufacturers
and researchers), acquirers, investors, and medical, scientific, business and financial advisors,
on a need-to-know basis in accordance with such Recipient’s exercise of its rights or performance
of its obligations under this Agreement; provided that such persons agree to be bound by
obligations of confidentiality with respect to such Proprietary Information which are substantially
similar in scope as those set forth in this Article 10.

(b) Recipient may disclose Proprietary Information of the Disclosing Party to government or
other regulatory authorities to the extent that such disclosure is (i) required by applicable law
(including all applicable securities laws), regulation, agency or court order, or (ii) is
reasonably necessary in connection with the prosecution of any Patent, to obtain any authorization
to conduct clinical studies, or to obtain any Approval for a Product; provided that, in case of any
disclosures required as described in clause (i) above, the Recipient shall provide reasonable
advance notice to the Disclosing Party to allow such Party to oppose such disclosure or to request
confidential treatment of such Proprietary Information.

 

15

 

10.3 Prior Agreements. This Agreement supersedes the Mutual Nondisclosure Agreement
between Licensee and ADVENTRX dated August 6, 2008 (the “Mutual Confidentiality
Agreement”). All information exchanged between the Parties under the Mutual Confidentiality
Agreement shall be deemed to have been disclosed under this Agreement on a going-forward basis and
shall be subject to the terms of this Article 10 as of the Effective Date.

10.4 Terms of Agreement. The terms of this Agreement shall not be disclosed by either
Party without the prior written consent of the other Party, which shall not be unreasonably
withheld; provided, however that either Party may make such a disclosure (a) to the extent
required by law or by the requirements of any nationally recognized securities exchange, quotation
system or over-the-counter market on which such Party has its securities listed or traded, or (b)
to any Affiliates, legal advisors, accountants, and, in each case whether actual or potential, to:
licensees, sublicensees or other collaboration partners with a reasonable need-to-know; acquirers,
investors; lenders and other potential financing sources, who are obligated to keep such
information confidential. In the event that such disclosure is required as described in clause (a)
of the preceding sentence, the disclosing Party shall make reasonable efforts to provide the other
Party with notice beforehand and to coordinate with the other Party with respect to the wording,
timing and any redactions of any such disclosure.

10.5 Press Release and Future Announcement. None of the Parties may issue a press
release with respect to this transaction, without the prior written consent of the other Party.
Once such press release or any other written statement is approved for disclosure by the Parties,
each Party may make subsequent public disclosure of the contents of such statement without the
further approval of the other Party. Notwithstanding the foregoing, Licensee acknowledges and
agrees that ADVENTRX may (i) publicly disclose (including by press release and through fillings
with the United States Securities and Exchange Commission) the occurrence/attainment of each
regulatory milestone set forth in Section 5.2 and commercial milestone set forth in Section 5.3 and
the amount and payment of associated payments, as well as notice and/or receipt of Sublicense
Revenue, and (ii) include in its public disclosures (including in “pipeline charts” summarizing
development and commercialization results and goals for ADVENTRX’s products and product candidates)
a general description of the stage of development of all Products, including gross sales and Net
Sales thereof.

ARTICLE 11

INTELLECTUAL PROPERTY AND INFRINGEMENT

11.1 General. Unless otherwise agreed in writing by the Parties, as between the
Parties, title to all inventions and other intellectual property made solely by personnel of
Licensee in connection with this Agreement shall be owned by Licensee, and title to all inventions
and other intellectual property made solely by personnel of ADVENTRX in connection with this
Agreement shall be owned by ADVENTRX.

11.2 Licensee Improvements. In the event that Licensee or its Affiliates or a
Sublicensee (i) invents, discovers or develops any improvement to Products or the subject matter of
any of the ADVENTRX Patents (“Product Improvement”), including without limitation any
modification to a Product or its components or its or its components manufacture or formulation
that enhances its safety, effectiveness, stability, administration or otherwise, or reduces its or
their cost, or (ii) acquires the right to grant a license to a Product Improvement, Licensee hereby
does, and agrees that its Affiliates and all Sublicensees hereby do, grant to ADVENTRX a
nonexclusive, perpetual, irrevocable, non-transferable (except in accordance with Section 15.2),
fully paid-up, worldwide license, with the right to sublicense, to Product Improvements, to use,
make, have made, sell, offer for sell, import and otherwise exploit Products.

11.3 Third Party License. In the event that Licensee has determined to enter into
discussions with a Third Party for a license to such Third Party’s intellectual property as it
relates to a Product, Licensee shall, as soon as is reasonably practicable, notify ADVENTRX and
provide ADVENTRX with all information, data and reports that Licensee has collected or developed
that relates to such Third Party intellectual property. In the event that ADVENTRX determines that
it desires to enter into discussions with such Third Party for such intellectual property, the
Parties shall cooperate in good faith to determine the best manner to initiate and continue
discussions with such Third Party for such Third Party intellectual property. For the avoidance of
doubt, the results of any discussions or negotiations with a Third Party shall not impact any of
the terms of this Agreement.

 

16

 

11.4 Patent Prosecution and Maintenance.

(a) By ADVENTRX. ADVENTRX (or its designee) shall have the right, at its option, to
control the preparation, filing, prosecution and maintenance of the ADVENTRX Patents, and Licensee
agrees to reimburse ADVENTRX for all of its out-of-pocket expenses in connection with such
activities in or related to the Territory as they are incurred. As used in this Section 11.4,
“prosecution” shall include interferences, re-examinations, reissues, oppositions, obtaining
certificates of correction, patent term extensions, Supplementary Protection Certificates, and the
like. ADVENTRX (or its designee) shall have the right to apply for an extension of the term of any
ADVENTRX Patent if available under the Drug Price Competition and Patent Term Restoration Act of
1984 and/or European, Japanese and other foreign counterparts of this law, including any foreign
laws extending marketing exclusivity for a Product, such as a Supplementary Protection Certificate.

(b) By Licensee. If ADVENTRX determines not to prosecute any ADVENTRX Patent within
the Territory, then ADVENTRX shall provide Licensee with written notice of such decision at least
sixty (60) days prior to the deadline for filing any such prosecution action for the ADVENTRX
Patent or the date on which the abandonment of any such ADVENTRX Patent would become effective. In
such event, Licensee shall have the right, but not the obligation, at its option and expense, to
control the preparation, filing, prosecution and maintenance of such ADVENTRX Patent in ADVENTRX’s
name in the Territory.

(c) Cooperation. Each Party shall cooperate with the other Party in connection with
activities relating to the preparation, filing, prosecution and maintenance of the ADVENTRX Patents
undertaken by the other Party pursuant to this Section 11.4, including: (i) making available to
such other Party in a timely manner any documents or information reasonably necessary or
appropriate to facilitate such other Party’s preparation, filing, prosecution and maintenance of
any ADVENTRX Patent; and (ii) if and as appropriate, signing (or causing to have signed) all
documents relating to the preparation, filing, prosecution and maintenance of any ADVENTRX Patent
by such other Party. Each Party shall also promptly provide to the other Party all information
reasonably requested by such other Party with regard to such Party’s activities pursuant to this
Section 11.4.

11.5 Enforcement.

(a) Notice. In the event either Party learns of any infringement of the ADVENTRX
Patents by the manufacture, use, sale, offer for sale or importation of any product in the
Territory (an “Infringement”), it shall promptly provide written notice to the other Party
of such Infringement and shall supply such other Party with all evidence it possesses pertaining to
such Infringement.

(b) Infringement Action. The Parties will discuss in good faith whether to bring any
action with respect to the Infringement. Licensee understands and agrees that ADVENTRX may notify
LPI of such infringement, and the Parties (and LPI if it desires) shall confer and endeavor to
reach consensus as to how best to deal with the infringer. If the Parties mutually determine to
proceed with enforcement, Licensee (directly or through its nominee) shall have the first right,
but not the obligation, to seek to abate such Infringement, or to file suit against the infringing
party for the Infringement, at its own cost and expense. In the event that Licensee or its nominee
does not, within one hundred twenty (120) days from date of a request by ADVENTRX to do so, take
action to abate such Infringement or file suit against the infringing party for the Infringement,
ADVENTRX (directly or through its nominee) shall have the right, but not the obligation, to enforce
the ADVENTRX Patents in connection with such Infringement, and at its own cost and expense.

 

17

 

(c) Cooperation. In any suit, action or other proceeding in connection with an
Infringement (an “Infringement Action”), the Party assuming the primary role in the
Infringement Action (“Controlling Party”) shall keep the non-Controlling Party reasonably
informed of the progress of such Infringement Action. The non-Controlling Party shall cooperate
fully with the Controlling Party, including by joining as a nominal party and executing such
documents as the Controlling Party may reasonably request, provided that neither ADVENTRX nor SDP
shall be required to transfer any right, title or interest in or to any of the ADVENTRX Patents to
Licensee, its Affiliates, Sublicensees or any other Third Party to confer standing to bring an
Infringement Action. In any case, the non-Controlling Party shall have the right, even if not
required to be joined, to participate in any Infringement Action with counsel of its own choice at
its own expense.

(d) Costs and Recoveries. The Controlling Party with respect to any Infringement
Action may not settle any such action, or otherwise consent to any adverse judgment in any such
action, that restricts the scope of, or admits the unenforceability or invalidity of, any ADVENTRX
Patent without the express written consent of the non-Controlling Party, which consent shall not be
unreasonably withheld. Any damages, monetary awards or other amounts recovered, whether by
judgment or settlement, pursuant to any suit, proceeding or other action taken under this
Section 11.5 shall applied as follows:

(i) First, to reimburse the Parties for their respective costs and expenses (including
reasonable attorneys’ and experts’ fees and costs) incurred in prosecuting such Infringement
Action;

(ii) Second, any amounts remaining shall be allocated seventy percent (70%) to the Controlling
Party and thirty percent (30%) to the non-Controlling Party.

For the avoidance of doubt, if any judgment or settlement results in the granting to the
alleged infringer of a sublicense of any of the ADVENTRX Technology with running royalties payable
on post-judgment/settlement sales by the alleged infringer, such alleged infringer shall be deemed
to be a Sublicensee and such royalties on post-settlement sales (x) shall be subject to all
applicable royalty obligations hereunder as if the product the subject of such judgment or
settlement were a Product, and (y) shall not be subject to this Section 11.5(d).

11.6 Defense of Infringement Claims. If any Product manufactured, used or sold by
Licensee, its Affiliates, or Sublicensees, becomes the subject of a Third Party’s claim or
assertion of infringement of a patent relating to the manufacture, use, sale, offer for sale or
importation of such Product, the Party first having notice of the claim or assertion shall promptly
notify the other Party, and the Parties shall promptly confer to consider the claim or assertion
and the appropriate course of action. Any such claim naming ADVENTRX or SDP as a defendant shall
be subject to Section 14.1. In any event, each Party shall reasonably assist the other Party and
cooperate in connection with any litigation, arbitration or similar proceedings in which such Party
is not named as a defendant, at the defending Party’s request and expense.

11.7 Labeling and Promotional Materials. Subject to applicable laws and regulations,
packaging for all Products sold by or on behalf of Licensee, its Affiliates, or Sublicensees
pursuant to this Agreement and on all package inserts and labeling will identify SDP (or its
successor assign) as licensor of the ADVENTRX Patents and will comply with all patent marking
requirements as specified in 35 USC Sec. 287 or other applicable patent marking requirements of
other jurisdictions to preserve and maximize the rights and remedies of SDP and ADVENTRX.

 

18

 

ARTICLE 12

TERM AND TERMINATION

12.1 Term. This Agreement shall commence on the Effective Date and, unless terminated
earlier pursuant to Sections 12.2, 12.3 or 12.4 shall continue in full force and effect until no
further royalties would be due. Upon expiration (but not early termination of this Agreement) in
accordance with this Section 12.1, the licenses and rights granted by ADVENTRX or SDP to Licensee
under this Agreement will continue on a fully paid-up, royalty-free basis.

12.2 Termination for Material Breach. If either Party materially breaches this
Agreement at any time, the non-breaching Party shall have the right to terminate this Agreement by
written notice to the breaching Party, if such breach is not cured within ninety (90) days (thirty
(30) days in the case of a failure to pay) after written notice is given by the non-breaching Party
to the breaching Party specifying the breach.

12.3 Termination for Financial Insecurity.  In the event that either Party files for
protection under bankruptcy laws, makes an assignment for the benefit of creditors, appoints or
suffers appointment of a receiver or trustee over its property, files a petition under any
bankruptcy or insolvency act or has any such petition filed against it which is not discharged
within sixty (60) days of the filing thereof, then the other Party may terminate this Agreement
effective immediately upon written notice to such Party.

12.4 Termination by Licensee. Subject to the requirements of this Section 12.4, this
Agreement may be terminated by Licensee, in its sole discretion, upon sixty (60) days written
notice to ADVENTRX; provided, however, that, prior to making a final determination to terminate
this Agreement (and prior to delivering any notice of termination) pursuant to this Section 12.4,
Licensee shall first notify ADVENTRX of facts and circumstances that Licensee is considering and
might cause Licensee to make a final determination to terminate this Agreement pursuant to this
Section 12.4 and Licensee shall discuss with ADVENTRX in good faith for at least thirty (30) days
following the date it notifies ADVENTRX that it is considering terminating this Agreement possible
means to address or otherwise resolve Licensee’s concerns.  Following such 30-day good faith
discussion period, Licensee may terminate this Agreement pursuant to this Section 12.4 provided any
notice to terminate is received by ADVENTRX within 10 days after the end of such 30-day good faith
discussion period.

12.5 Effect of Expiration or Termination.

(a) Termination. Upon termination of this Agreement:

(i) The licenses and rights granted to Licensee under Article 2 will immediately terminate;
provided that, at ADVENTRX’s option, any sublicenses granted in accordance with Section 2.4 and to
alleged infringers as contemplated by Section 11.5 prior to the date of the corresponding notice of
breach (in the case of Section 12.2) or termination (in the case of Section 12.3 or 12.4) issued by
ADVENTRX shall survive if the relevant Sublicensee agrees in writing to be bound by the terms of
this Agreement as such terms apply to such Sublicensee (in which event, such Sublicensee will be
deemed a direct licensee of SDP (or its assignee or successor, as the case may be).

(ii) Licensee’s royalty and milestone obligations (other than royalty payments under Section
5.5), and related reporting obligations and audit rights, under this Agreement shall survive for
the royalty term set forth in Section 5.4(e)(ii).

 

19

 

(iii) Licensee shall, as promptly as is reasonably practicable and in any event within thirty
(30) days, return to ADVENTRX all ADVENTRX Know-How, and all copies and any other tangible and
electronic embodiments thereof in Licensee’s, its Affiliates’, or any Sublicensee’s possession,
subject to the rights of any surviving Sublicensee.

(iv) Licensee shall, as promptly as is reasonably practicable and in any event within thirty
(30) days, provide to ADVENTRX all copies of any Regulatory Approvals, and related filings, and
copies of all materials in Licensee’s control or possession related to the manufacture,
preparation, formulation, use, development, marketing, promotion, use, handling, storage, sale and
commercialization of each Product.

(v) Licensee shall comply with Section 8.6.

(b) Survival of Certain Obligations. The expiration or termination of this Agreement
for any reason shall not relieve either Party of any obligation accruing on or prior to such
expiration or termination, or which is attributable to a period prior to such expiration or
termination, nor preclude either Party from pursuing any rights and remedies it may have under this
Agreement, or at law or in equity, which accrued or are based upon any event occurring prior to
such expiration or termination. The following provisions shall survive the expiration or
termination of this Agreement for any reason: Articles 6 (Payments), 7 (Reports, Records and
Accounting), 10 (Confidentiality), 14 (Indemnification and Insurance) and 15 (Miscellaneous) and
Sections 8.3 (Adverse Events, with respect to Products distributed in the Territory during the
Term), 8.6 (Ownership), and 12.5 (Effect of Expiration or Termination).

ARTICLE 13

REPRESENTATIONS AND WARRANTIES

13.1 General Representations and Warranties. Each Party represents and warrants to
the other Party that:

(a) it is a corporation duly organized and validly existing under the laws of the jurisdiction
in which it is incorporated;

(b) it has full corporate power and authority, and has obtained all approvals, permits and
consents necessary, to enter into this Agreement and to perform its obligations hereunder;

(c) this Agreement is legally binding upon it and enforceable in accordance with its terms;
and

(d) the execution, delivery and performance of this Agreement does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a party or by which it may
be bound, nor violate any material law or regulation of any governmental or regulatory authority
having jurisdiction over it.

13.2 Additional Warranties of ADVENTRX/SDP. ADVENTRX and SDP hereby covenant,
represent and warrant to Licensee that:

(a) ADVENTRX or SDP, as the case may be, has the right to grant the licenses to Licensee that
are set forth in this Agreement; and

(b) Neither ADVENTRX nor SDP has granted any rights in the ADVENTRX Technology that are
inconsistent with or that limit the rights granted to Licensee under this Agreement;

 

20

 

13.3 DISCLAIMER. Nothing in this Agreement is or shall be construed as a warranty or
representation by ADVENTRX or SDP as to the validity or scope of any patent application or patent
licensed or accuracy or usefulness of any know-how or materials hereunder or a warranty or
representation that anything made, used, sold or otherwise disposed of under any license granted
pursuant to this Agreement is or will be free from infringement of patents, copyrights, and other
rights of third parties. Except as expressly set forth in this Agreement, NEITHER PARTY MAKES ANY
REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO
EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR OF
NON-INFRINGEMENT OF ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF THIRD PARTIES, OR ANY
OTHER EXPRESS OR IMPLIED WARRANTIES.

ARTICLE 14

INDEMNIFICATION AND INSURANCE

14.1 Indemnification by Licensee. Licensee shall defend, indemnify, and hold harmless
ADVENTRX, SDP, its and their Affiliates and their respective directors, officers, shareholders,
employees and agents, and their respective heirs, successors and assigns (“ADVENTRX
Indemnitees”), from and against any and all liabilities, claims, damages, losses, costs and
expenses (including reasonable attorneys’ and experts’ fees and other costs of defense) owing to
Third Parties (collectively, “Liabilities”) suffered or sustained by an ADVENTRX
Indemnitee, or to which an ADVENTRX Indemnitee becomes subject, (i) resulting directly or
indirectly from the advertising, promotion, marketing, manufacture, use, handling, storage, sale or
other disposition of or development or commercialization activities related to a Product by
Licensee, its Affiliates, or Sublicensees or their respective agents and distributors, but only to
the extent that such claims do not result from the negligence or intentional misconduct of ADVENTRX
or SDP, or (ii) resulting directly from a breach of this Agreement by Licensee.

14.2 Indemnification by ADVENTRX. ADVENTRX shall defend, indemnify, and hold harmless
Licensee, its Affiliates and their respective directors, officers, shareholders, employees and
agents, and their respective heirs, successors and assigns (“Licensee Indemnitees”), from
and against any and all Liabilities suffered or sustained by a Licensee Indemnitee, or to which a
Licensee Indemnitee becomes subject, (i) resulting from any negligence or intentional misconduct of
ADVENTRX or SDP, or (ii) resulting directly from a breach of this Agreement by ADVENTRX or SDP.

14.3 Indemnification Procedures. In the event that any Indemnitee (either a Licensee
Indemnitee or an ADVENTRX Indemnitee) intends to claim indemnification under this Article 14, such
Indemnitee shall promptly notify the other Party in writing of the alleged Liability. The
indemnifying Party (“Indemnifying Party”) shall have the right to control the defense
thereof, provided that counsel for the Indemnifying Party, who shall conduct the defense of such
claim or any litigation resulting therefrom, shall be approved by the Indemnitee (which approval
shall not be unreasonably withheld), and the Indemnitee may participate in such defense at such
Indemnitee’s expense (unless the Indemnitee shall have reasonably concluded, based upon a written
opinion from outside legal counsel, that there may be a conflict of interest between the
Indemnifying Party and the Indemnitee in the defense of such action, in each of which cases the
Indemnifying Party shall pay the fees and expenses of one law firm serving as counsel for the
Indemnitee). The failure of any Indemnitee to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Agreement to the extent that such failure to give
notice did not result in material prejudice to the Indemnifying Party or the Indemnifying Party’s
insurer. The Indemnifying Party, in the defense of any such claim or litigation, shall not, except
with the approval of the Indemnitee (which approval shall not be unreasonably withheld), consent to
entry of any judgment or enter into any settlement which (i) would result in injunctive or other
relief being imposed against the Indemnitee; or (ii) does not include as an unconditional term
thereof the giving by the claimant or plaintiff to such Indemnitee of a release from all liability
in respect to such claim or litigation. The Indemnitee shall furnish such information regarding
itself or the claim in question as the Indemnifying Party may reasonably request in writing, and
shall be reasonably required in connection with the defense of such claim or litigation resulting
therefrom.

 

21

 

14.4 Insurance. Prior to the initiation of the first clinical trial for a Product and
during the term of this Agreement, Licensee shall obtain and maintain appropriate comprehensive,
commercial general liability and product liability insurance with respect to Licensed Products and
any clinical trial for a Product, including coverage types and amounts that Licensee typically
obtains in connection with the conduct of clinical trial with human subjects in the Territory, and
in any event, of at least the scope of coverage and amounts standard in the industry for the
Territory. Such insurance shall name ADVENTRX, SDP, and their Affiliates as additional insureds
and shall be primary and shall not participate with nor be excess over any valid and collectable
insurance or program of self-insurance carried or maintained by ADVENTRX, SDP, and their
Affiliates. At ADVENTRX’s request, Licensee shall provide ADVENTRX with a certificate of such
insurance and shall promptly notify ADVENTRX of any change in the terms of insurance from those set
forth in the most recent certificate of insurance provided to ADVENTRX pursuant to this Section.
Such insurance shall be in effect not later than the first administration of such a Licensed
Product in humans. Licensee shall require Sublicensees and Affiliates, if performing clinical
trials or offering for sale or selling any Product, to carry equivalent insurance and to comply
with all provisions of this Section.

ARTICLE 15

MISCELLANEOUS

15.1 Force Majeure. Neither Party shall be held liable or responsible to the other
Party, nor be deemed to have defaulted under or breached this Agreement, for failure or delay in
fulfilling or performing any term of this Agreement to the extent, and for so long as, such failure
or delay is caused by or results from causes beyond the reasonable control of the affected Party
(“Force Majeure Event”), including fire, floods, embargoes, power shortage or failure, acts
of war (whether war be declared or not), insurrections, riots, terrorism, civil commotions,
strikes, lockouts or other labor disturbances, acts of God or other deities (including lesser gods)
or any acts, omissions or delays in acting by any governmental authority or the other Party;
provided the affected Party uses reasonable best efforts to mitigate the impact of such Force
Majeure Event and resume performance under this Agreement. Notwithstanding the foregoing, in the
event that any default or breach continues for more than one hundred eighty (180) days due to a
Force Majeure Event or series of Force Majeure Events, the other Party may terminate this Agreement
upon thirty (30) days prior written notice. For the avoidance of doubt, a failure to pay shall
never be excused by a Force Majeure Event.

15.2 Assignment. Neither Party may assign or transfer (including through operation of
law, reverse triangular merger or otherwise) this Agreement without the prior written consent of
the other Party, except (i) to an entity who acquires all or substantially all of its assets or
business related to the subject matter of this Agreement, whether through merger, sale of stock,
sale of assets, exclusive transfer of technology, reorganization or otherwise, (ii) with respect to
ADVENTRX, to an entity who acquires (by any of the foregoing methods) ADVENTRX’s ANX-514 program
and (iii) with respect to SDP, to ADVENTRX. Any permitted assignee shall assume all obligations of
its assignor under this Agreement. Any purported assignment by a Party of this Agreement in
violation of this Section 15.2 shall be void. For the avoidance of doubt, nothing in this Section
15.2 or elsewhere in this Agreement shall restrict ADVENTRX from transferring, assigning or selling
its right to receive payment hereunder.

 

22

 

15.3 Severability. If one (1) or more provisions of this Agreement is held to be
invalid, illegal or unenforceable, the Parties shall substitute, by mutual consent, valid
provisions for such invalid, illegal or unenforceable provisions which valid provisions are, in
their economic effect, sufficiently similar to the invalid provisions that it can be reasonably
assumed that the Parties would have entered into this Agreement with such provisions. In the event
that such provisions cannot be agreed upon, the invalidity, illegality or unenforceability of
one (1) or more provisions of the Agreement shall not affect the validity of this Agreement as a
whole.

15.4 Notices. Any notice, consent or report required or permitted to be given or made
under this Agreement by one Party to the other Party shall be in English and in writing, delivered
personally or by facsimile (receipt verified and a copy promptly sent by personal delivery, U.S.
first class mail or express courier providing evidence of receipt, postage prepaid (where
applicable)), or by U.S. first class mail or express courier providing evidence of receipt, postage
prepaid (where applicable), at the following address for a Party (or such other address for a Party
as may be specified by like notice):

	 	 	 
	To ADVENTRX:	 	To Licensee:
	 
	 	 
	ADVENTRX Pharmaceuticals, Inc.

	 	Shin Poong Pharmaceutical Co., Ltd.
	6725 Mesa Ridge Road, Suite 100

	 	748-31 Yoksam-Dong, Kangnam-Ku
	San Diego, CA 92121

	 	Seoul 135-952 Korea
	Attention: Vice President, Legal

	 	Attention: Vice President
	Facsimile: (858) 552-0876

	 	Facsimile: 82-2-3452-2866
	Phone: (858) 552-0866

	 	Phone: 82-2-2189-3470
	 
	 	 
	With a copy to:

	 	With a copy to:
	 
	 	 
	ADVENTRX Pharmaceuticals, Inc.

	 	Shin Poong Pharmaceutical Co., Ltd.
	6725 Mesa Ridge Road, Suite 100

	 	748-31 Yoksam-Dong, Kangnam-Ku
	San Diego, CA 92121

	 	Seoul 135-952 Korea
	Attention: Vice President, Business Development

	 	Attention: Managing Director, Business Development
	Facsimile: (858) 552-0876

	 	Facsimile: 82-2-553-2578
	Phone: (858) 552-0866

	 	Phone: 82-2-2189-3556

All such notices, consents or reports shall be effective upon receipt.

15.5 Applicable Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of California and the United States, excluding the Convention on
Contracts for the International Sale of Goods and that body of law known as conflicts of laws.

15.6 Arbitration.

(a) Any dispute arising out of or related to this Agreement shall be finally settled in
accordance with the Rules of Arbitration of the International Chamber of Commerce by one arbitrator
appointed in accordance with such Rules. The arbitration shall take place in San Diego,
California, but the Parties hereby agree to exclude any right of application or appeal to the
courts in connection with any question of law arising in the course of the arbitration or out of
the award. The arbitration shall be conducted in the English language. Relevant documents in
other languages shall be translated into English if the arbitrator so directs. The applicable
procedural law shall be the law of the place of arbitration. The Parties agree that they will,
before the hearing of any dispute, make discovery and disclosure of all materials relevant to the
subject matter of such dispute. A written transcript in English of the hearing will be made and
furnished to the Parties. Examination of witnesses by the parties and by the arbitrators will be
permitted. The arbitrator will decide in accordance with the terms of this Agreement (i.e., the
terms hereof) and will take into account any appropriate international trade usages applicable to
the transaction. The arbitrator will state the reasons upon which the award is based. The award
of the arbitrator will be final and binding upon the Parties. Judgment upon the award may be
entered in any court having jurisdiction. An application may be made to any such court for
judicial acceptance of the award and an order of enforcement.

(b) Pending the selection of the arbitrator or pending the arbitrator’s determination of the
merits of any dispute, either Party may seek appropriate interim or provisional relief from any
court of competent jurisdiction as necessary to protect the rights or property of that Party.

 

23

 

15.7 LIMITATION OF LIABILITY. EXCEPT FOR A BREACH OF ARTICLE 10 (CONFIDENTIALITY) OR
FOR INTENTIONAL BREACHES OF THIS AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY
PUNITIVE, SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES ARISING OUT OF THIS AGREEMENT,
HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY; PROVIDED HOWEVER THAT NOTHING IN THIS SECTION 15.7
SHALL BE DEEMED TO LIMIT THE INDEMNIFICATION OBLIGATIONS OF EITHER PARTY UNDER ARTICLE 14 TO THE
EXTENT A THIRD PARTY RECOVERS ANY PUNITIVE, SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES
FROM AN INDEMNITEE.

15.8 Entire Agreement. This Agreement (including the Exhibits attached hereto)
contains the entire agreement by the Parties with respect to the subject matter hereof and
supersedes any prior express or implied agreements, understandings and representations, either oral
or written, which may have related to the subject matter hereof in any way.

15.9 English Language. This Agreement is written in the English language, which shall
be controlling for all purposes. No translation of this Agreement into any other language shall be
of any force or effect in the interpretation of this Agreement or in a determination of the intent
of the Parties.

15.10 Interpretation. The captions to the several Articles and Sections of this
Agreement are not a part of this Agreement, but are included for convenience of reference and shall
not affect its meaning or interpretation. In this Agreement: (a) the word “including” shall be
deemed to be followed by the phrase “without limitation” or like expression; (b) the singular shall
include the plural and vice versa; and (c) masculine, feminine and neuter pronouns and expressions
shall be interchangeable.

15.11 Independent Contractors. It is expressly agreed that ADVENTRX and Licensee
shall be independent contractors and that the relationship between the two Parties shall not
constitute a partnership, joint venture or agency or other fiduciary relationship. Neither
ADVENTRX nor Licensee shall have the authority to make any statements, representations or
commitments of any kind, or to take any action, which shall be binding on the other Party, without
the prior written consent of the other Party to do so.

15.12 Waiver; Amendment. Except as otherwise expressly provided in this Agreement,
any term of this Agreement may be waived only by a written instrument executed by the Party waiving
compliance. The delay or failure of any Party at any time to require performance of any provision
of this Agreement shall in no manner affect such Party’s rights at a later time to enforce the
same. This Agreement may be amended, and any term of this Agreement may be modified, only by a
written instrument executed by each Party.

15.13 Binding Effect. This Agreement shall be binding upon and inure to the benefit
of the Parties and their respective legal representatives, successors and permitted assigns.

15.14 Counterparts. This Agreement may be executed in two (2) or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument.

[Remainder of page intentionally left blank; signature page follows.]

 

24

 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth
above.

	 	 	 	 	 	 	 
	ADVENTRX PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 
	BY:	 	/s/ Brian M. Culley	 	 
	 	 	 	 	 
	 

	 	NAME:
	 	Brian M. Culley	 	 
	 

	 	TITLE:
	 	Chief Business Officer	 	 
	 
	 	 	 	 	 	 
	SHIN POONG PHARMACEUTICAL CO., LTD.	 	 
	 
	 	 	 	 	 	 
	BY:	 	/s/ Kim Byung Hwa	 	 
	 	 	 	 	 
	 

	 	NAME:
	 	Byung Hwa Kim	 	 
	 

	 	TITLE:
	 	CEO & President	 	 
	 
	 	 	 	 	 	 
	SD PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 
	BY:	 	Brian M. Culley	 	 
	 	 	 	 	 
	 

	 	NAME:
	 	Brian M. Culley	 	 
	 

	 	TITLE:
	 	Vice President	 	 

 

25

 

EXHIBIT A

ADVENTRX PATENTS

WO/2007/0899311 VITAMIN E SUCCINATE STABILIZED PHARMACEUTICAL COMPOSITIONS, METHODS FOR THE
PREPARATION AND THE USE THEREOF

International Application No. PCT/US2007/002929

WO/2006/037089 LOW OIL EMULSION COMPOSITIONS FOR DELIVERING TAXOIDS AND OTHER INSOLUBLE DRUGS

International Application No. PCT/US2005/034971

 

 

 

EXHIBIT B

ADVENTRX KNOW-HOW

***

	 	 	 
	***	 	Portions of this page have been omitted pursuant to a
request for Confidential Treatment filed separately with the Commission.

 

 

 

EXHIBIT C

DEVELOPMENT PLAN

	1.	 	Licensee shall be responsible for any research and development, including non-clinical
and clinical studies of the Product, in the Territory.

	2.	 	Licensee will undertake necessary steps to obtain Regulatory Approval for marketing of
the Product in the Territory. The application for such Regulatory Approval
(“Regulatory Application”) will be
*** Licensee will provide ADVENTRX with all notices and other correspondence with
Regulatory Authorities relating to the Regulatory Application.

	3.	 	Unless *** Licensee will submit a Regulatory Application (that it has prepared with
good faith, diligent efforts) for the Product in the Territory *** and receiving ***. ***.

	4.	 	Licensee will use all commercially reasonable efforts to meet the demands of the
Regulatory Authority relating to any Regulatory Application, any maintenance of each
Regulatory Approval or any application to vary or renew each Regulatory Approval.

	 	 	 
	***	 	Portions of this page have been omitted pursuant to a
request for Confidential Treatment filed separately with the Commission.

 

-2-

 

EXHIBIT D

LETTER FROM CONTRACT MANUFACTURER

 

-3-

 

***

March 5, 2009

BY COURIER

ADVENTRX Pharmaceuticals, Inc.

Attn: Brian Culley

6725 Mesa Ridge Road, Suite 100

San Diego, CA 92121

To Whom It May Concern:

It is the understanding of *** (“***”) that certain companies are negotiating with ADVENTRX
Pharmaceuticals, Inc. (“Company”) regarding the terms of a definitive agreement pursuant to which
one of such companies (“Licensee”) would take a license under certain Company patents and/or patent
applications to sell Company’s product candidate ANX-514 (docetaxel emulsion) (“Product”) in South
Korea (“Territory”).

As of the date of this letter, *** and Company are parties to an agreement for certain services
related to, among other things, ***. *** has communicated to Company its interest and desire to
supply Product to licensees of Company. Subject to any necessary consent from Company, this letter
confirms ***’s intent and desire to negotiate with Licensee in good faith for *** to Licensee for
sale in the Territory. Any such supply will be pursuant to a definitive agreement to be mutually
negotiated and agreed upon by *** and Licensee.

It is understood that this letter constitutes a statement of our intention with respect to the
proposed transactions; a binding commitment with respect to the transactions will result only from
the execution and delivery of the definitive agreement expressed therein.

Sincerely,

***

	 	 	 	 	 
	By:

	 	/s/ ***	 	 
	 

	 	 

***, Managing Director
	 	 

	 	 	 
	***	 	Portions of this page have been omitted pursuant to a
request for Confidential Treatment filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}]]